Ally Qiuling He, PhD serves as Vice President, Head of Biometrics at Hemab. Ally brings over 13 years of experience in drug development through early to late stages, with a focus in rare diseases and oncology. Before Hemab, Ally has worked with increasing responsibilities at Novartis Institute of Biomedical Research, Alnylam Therapeutics and Agios Therapeutics, and her most recent role was Head of Biostatistics at CRISPR Therapeutics. Her work has directly contributed to several product approvals and RMAT/ Breakthrough designations. Ally received her PhD in Statistics from University of Wisconsin-Madison.